摘要
从新中国成立至今70年,我国眼底病诊疗水平飞速提高。国际上新的治疗方法、新的药物不断被引入国内(如雷珠单抗、阿柏西普、地塞米松缓释剂等),极大地促进了我国眼底病治疗的发展。尤其是以抗VEGF药物为代表的小分子抗体药物的出现,以及玻璃体注射给药方式的推广,是眼底病治疗领域具有里程碑意义的进展,改变了既往对眼底血管性疾病的治疗方式,降低了玻璃体手术的数量,极大地改善了疾病预后。国产全人源化重组融合蛋白康柏西普丰富了抗VEGF药物谱。随着眼底疾病治疗药物的进展,治疗技术的多样化,我国眼底病的治疗水平也进一步与国际接轨。
Since the founding of New China 70 years ago, the level of diagnosis and treatment of fundus diseases in China has been rapidly improved. New treatment methods and new drugs have been introduced into China, such as Ranibizumab, Afibercept, dexamethasone sustained-release agents, etc., which has greatly promoted the development of treatment of fundus diseases in China. Especially the emergence of small molecule antibody drugs represented by anti-vascular endothelial growth factor (VEGF) drugs and the promotion of intravitreal injection are milestones in the field of fundus disease treatment, which has changed the previous treatment methods for fundus vascular diseases, reduced the amount of vitrectomy, greatly improved the prognosis of the disease. Homemade humanized recombinant fusion protein Conbercept enriches the spectrum of anti-VEGF drugs. With the development of medicine and diversification of treatment technology for fundus diseases, the treatment level of fundus diseases in China is further in line with the international standards.
作者
周楠
魏文斌
ZHOU Nan;WEI Wen-bin(Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China)
出处
《眼科》
CAS
2019年第5期321-324,共4页
Ophthalmology in China
关键词
眼底病
药物治疗
fundus diseases
medical treatment
